• Els L van Persijn van Meerten, Hans Gelderblom, and Johan L Bloem.
• Department of Radiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. epersijn@lumc.nl
• Eur Radiol. 2010 Jun 1; 20 (6): 1456-67.

AbstractThe purpose of this review article is to familiarize radiologists with the recently revised Response Evaluation Criteria in Solid Tumours (RECIST), used in many anticancer drug trials to assess response and progression rate. The most important modifications are: a reduction in the maximum number of target lesions from ten to five, with a maximum of two per organ, with a longest diameter of at least 10 mm; in lymph nodes (LNs) the short axis rather than the long axis should be measured, with normal LN measuring <10 mm, non-target LN >or=10 mm but <15 mm and target LN >or=15 mm; osteolytic lesions with a soft tissue component and cystic tumours may serve as target lesions; an additional requirement for progressive disease (PD) of target lesions is not only a >or=20% increase in the sum of the longest diameter (SLD) from the nadir but also a >or=5 mm absolute increase in the SLD (the other response categories of target lesion are unchanged); PD of non-target lesions can only be applied if the increase in non-target lesions is representative of change in overall tumour burden; detailed imaging guidelines. Alternative response criteria in patients with hepatocellular carcinoma and gastrointestinal stromal tumours are discussed.

14 keywords...

hide…